Another study reported that higher levels of plasma CD9+/CD63+ and PD-L1+/CD63+ EVs correlated with adverse clinical features, therapeutic failure and poor outcomes in patients with DLBCL [49]. Here, CD63 is linked to diffuse large B-cell lymphoma.